1. Clinical Overview
Artesunate is a potent, water-soluble, semi-synthetic derivative of artemisinin, a sesquiterpene lactone endoperoxide extracted from the plant Artemisia annua. It is a first-line antimalarial agent for the treatment of severe and complicated Plasmodium falciparum malaria, as per WHO and National Center for Vector Borne Diseases Control (NCVBDC), India guidelines. It acts rapidly to reduce parasite biomass and is the drug of choice for initial parenteral therapy in severe malaria, often followed by a full course of an appropriate oral ACT (Artemisinin-based Combination Therapy).
| Onset | Duration | Bioavailability |
|---|---|---|
| Intravenous: Parasite clearance time is typically 24-48 hours. Clinical improvement (e.g., reduction in fever, improved consciousness) can be seen within hours. | Short. The terminal half-life is approximately 45 minutes (for the parent drug). Its active metabolite, dihydroartemisinin (DHA), has a half-life of 1-2 hours. This necessitates multiple dosing or combination with longer-acting partner drugs. | Oral: ~60-70%. Intramuscular: ~85%. Intravenous: 100%. |
2. Mechanism of Action
Artesunate's antimalarial activity is attributed to its endoperoxide bridge. Inside the infected erythrocyte, the iron-rich environment (heme from hemoglobin digestion) catalyzes the cleavage of this endoperoxide bridge. This reaction generates highly reactive carbon-centered free radicals and reactive oxygen species (ROS). These reactive intermediates alkylate and oxidize vital parasite proteins (including PfATP6, a sarcoplasmic-endoplasmic reticulum calcium ATPase or SERCA), damage parasite membranes, and cause widespread macromolecular damage, leading to rapid parasite death.
3. Indications & Uses
- Severe and complicated Plasmodium falciparum malaria (initial parenteral therapy)
- Cerebral malaria
- Uncomplicated Plasmodium falciparum malaria (as part of an Artemisinin-based Combination Therapy - ACT)
4. Dosage & Administration
Adult Dosage: Severe Malaria (IV/IM): 2.4 mg/kg body weight at 0, 12, and 24 hours, then once daily until oral therapy can be started (usually for a minimum of 3 doses). Uncomplicated Malaria (Oral ACT): As part of a fixed-dose combination. Common Indian ACT is Artesunate (100mg) + Sulfadoxine (500mg) + Pyrimethamine (25mg) as a single daily dose for 3 days. The 60mg strength is often used for pediatric dosing or in specific combinations.
Administration: IV Injection: Reconstitute powder with 1 mL of 5% Sodium Bicarbonate solution provided. Shake gently for 2-3 minutes until clear. Then dilute to 5 mL with 5% Dextrose or Normal Saline. Administer by slow IV bolus over 3-5 minutes. IM Injection: Reconstitute as above and administer deep intramuscularly into the anterior thigh. Oral: Should be taken with food to enhance absorption and reduce GI upset. Always complete the full 3-day course of ACT.
5. Side Effects
Common side effects may include:
- Transient neutropenia (reversible within 1-2 weeks)
- Post-artemisinin delayed hemolysis (PADH) - occurring 1-3 weeks after treatment
- Nausea, vomiting, abdominal pain
- Headache, dizziness
- Transient elevation of liver enzymes (AST/ALT)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Strong CYP2A6 Inducers (e.g., Rifampicin) | May increase metabolism of DHA, potentially reducing its plasma concentration and efficacy. | Moderate |
| Antiretroviral Protease Inhibitors (e.g., Lopinavir/Ritonavir) | May increase artesunate/DHA levels; clinical significance unknown. | Moderate |
| Other QT-prolonging drugs (e.g., Antiarrhythmics, Fluoroquinolones) | Theoretical additive risk of QTc prolongation. | Mild |
| Chloroquine | Antagonistic interaction reported in vitro; not recommended for combination. | Major |
7. Patient Counselling
- DO complete the full 3-day course of medicine even if you feel better after 1-2 days.
- DO take the oral tablets with food.
- DO inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- DONT take any other antimalarial (like chloroquine) unless prescribed by your doctor.
- DONT skip follow-up blood tests to ensure parasite clearance.
8. Toxicology & Storage
Overdose: Limited data. Potential symptoms include severe dizziness, nausea, vomiting, cardiac conduction abnormalities (bradycardia, QTc prolongation), and hemolysis.
Storage: Store below 30°C. Protect from moisture. The powder for injection should be stored in its original packaging. After reconstitution for IV/IM use, the solution should be used immediately. Do not freeze.